CTMX Live-Signale | Maximieren Sie Profite mit Getagraph.com

Live Chart Being Loaded With Signals

Commentary (31 Mai 2024 @ 22:00):

Stats
Tagesvolumen	950 258
Durchschnittsvolumen	6.45M
Marktkapitalisierung	132.46M
EPS	$0 ( 2024-05-14 )
Nächstes Ertragsdatum	( $0 ) 2024-08-06
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	8.10
ATR14	$0.00400 (0.24%)

Insider Trading

Date	Person	Action	Amount	type
2024-05-15	Young Matthew P.	Buy	38 000	Stock Option (Right to Buy)
2024-05-15	Su Zhen	Buy	38 000	Stock Option (Right to Buy)
2024-05-15	Mohindru Mani	Buy	38 000	Stock Option (Right to Buy)
2024-05-15	Meyers James R	Buy	38 000	Stock Option (Right to Buy)
2024-05-15	Jones Elaine V	Buy	38 000	Stock Option (Right to Buy)

INSIDER POWER
67.38
Last 98 transactions
Buy: 4 955 428 \| Sell: 1 092 240

Volumen Korrelation

Lang: -0.54 (weak negative)

Kurz: -0.47 (neutral)

Signal:(18.208) Neutral

CytomX Therapeutics Inc Korrelation

10 Am meisten positiv korreliert
OZEM	1
LOGC	0.91
NALFX	0.894
BWIN	0.893
IIXIX	0.892
RGSVX	0.888
RGIVX	0.888
ANTUX	0.887
PGJZX	0.883
INFR	0.879

10 Am meisten negativ korreliert
PLTNU	-0.886
LDWY	-0.847
AAPD	-0.83
BRLSW	-0.828
CGON	-0.818
PXMD	-0.812

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

CytomX Therapeutics Inc Korrelation - Währung/Rohstoff

0.78
( moderate )

0.76
( moderate )

0.00
( neutral )

-0.64
( weak negative )

CytomX Therapeutics Inc Finanzdaten

Annual	2023
Umsatz:	$101.21M
Bruttogewinn:	$99.04M (97.85 %)
EPS:	$-0.00770

FY	2023
Umsatz:	$101.21M
Bruttogewinn:	$99.04M (97.85 %)
EPS:	$-0.00770

FY	2022
Umsatz:	$53.16M
Bruttogewinn:	$47.31M (88.98 %)
EPS:	$-1.480

FY	2021
Umsatz:	$69.57M
Bruttogewinn:	$69.57M (100.00 %)
EPS:	$-1.300

Financial Reports:

Symbol	Period	Year	Title
CTMX	Q1	2024	Q1 2024 Financial Performance Analysis of CytomX Therapeutics Inc.

CytomX Therapeutics Inc Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

CytomX Therapeutics Inc

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma; BMS-986249, a CTLA-4 Probody therapeutic drug, which is in Phase I/II clinical trials for the treatment of metastatic melanoma; and BMS-986288, an anti-CTLA-4 Probody drug, which is in Phase I clinical trials for the treatment of solid tumors. It also develops CX-2043, a conditionally activated ADC targeting the epithelial cell adhesion molecule, as well as CX-904, a conditionally activated epidermal growth factor receptor for the treatment of solid tumor. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc. to develop Probody therapeutics. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.